Home/Filings/4/0000950170-24-041039
4//SEC Filing

Rizvi Syed Ali-aamir 4

Accession 0000950170-24-041039

CIK 0001661460other

Filed

Apr 2, 8:00 PM ET

Accepted

Apr 3, 4:03 PM ET

Size

7.2 KB

Accession

0000950170-24-041039

Insider Transaction Report

Form 4
Period: 2024-04-01
Rizvi Syed Ali-aamir
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2024-04-01+185,000185,000 total
  • Award

    Employee Stock Option (Right to Buy)

    2024-04-01+250,000250,000 total
    Exercise: $3.10Exp: 2034-03-31Common Stock (250,000 underlying)
Footnotes (2)
  • [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments.
  • [F2]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter.

Documents

1 file

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother

Related Parties

1
  • filerCIK 0001897621

Filing Metadata

Form type
4
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 4:03 PM ET
Size
7.2 KB